Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RB1 loss |
| Therapy | Palbociclib |
| Indication/Tumor Type | estrogen-receptor positive breast cancer |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RB1 loss | estrogen-receptor positive breast cancer | resistant | Palbociclib | Preclinical - Cell culture | Actionable | In a preclinical study, RB1 loss was associated with acquired resistance to Ibrance (palbociclib) in an estrogen-receptor positive breast cancer cell line in culture (PMID: 27020857). | 27020857 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27020857) | Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. | Full reference... |